อนุภาคเหมือนไวรัส (Pseudovirus): การสร้างและการประยุกต์ใช้
คำสำคัญ:
การประยุกต์ใช้อนุภาคเหมือนไวรัส , โปรตีนเปลือกหุ้มของไวรัส , สารพันธุกรรมของไวรัส , อนุภาคเหมือนไวรัสบทคัดย่อ
อนุภาคเหมือนไวรัสเป็นโครงสร้างของโปรตีนเปลือกหุ้มของไวรัสที่ประกอบกันเป็นอนุภาคไวรัส โดยที่ขนาดและรูปร่างคล้ายคลึงกับไวรัสที่พบในธรรมชาติแต่ขาดสารพันธุกรรมของไวรัส ทำให้อนุภาค เหมือนไวรัสไม่สามารถเพิ่มจำนวนและไม่ทำให้เกิดโรคได้ ด้วยเหตุนี้ในปัจจุบันจึงมีการศึกษาเกี่ยวกับ อนุภาคเหมือนไวรัสและการประยุกต์ใช้อนุภาคเหมือนไวรัสกันอย่างแพร่หลาย บทความปริทัศน์นี้ จะอธิบายถึงวิธีการสร้างอนุภาคเหมือนไวรัส รูปร่างของอนุภาคเหมือนไวรัส การแสดงออกของรีคอมบิแนนท์โปรตีนเปลือกหุ้มของไวรัสในการแสดงออกระบบต่างๆ การทำรีคอมบิแนนท์โปรตีนเปลือกหุ้ม ของไวรัสให้บริสุทธิ์ การตรวจสอบอนุภาคเหมือนไวรัสและการประยุกต์ใช้อนุภาคเหมือนไวรัสในด้านต่างๆ ซึ่งได้แก่ การนำามาใช้เป็นวัคซีน การนำมาใช้เป็นพาหะในการนำาส่งกรดนิวคลีอิก การนำมาใช้เป็นพาหะในการนำส่งยาและการใช้อนุภาคเหมือนไวรัสสำหรับติดตามหรือถ่ายภาพ
References
Zeltins A. Construction and characterization of virus-like particle: A Review. Mol Biotechnol 2013; 53: 92-107.
Hou L, Wu H, Xu L, Yang F. Expression and self-assembly of virus-like particles of infectious hypodermal and hematopoietic necrosis virus in Escherichia coli. Arch Virol 2009; 154: 547-53.
Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA 1965; 191: 541–46.
Yan D, Wei YQ, Guo HC, Sun SQ. The application of virus-like particles as vaccines and biological vehicles. Appl Microbiol Biotechnol 2015; 99: 10415-32.
Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s syndrome and hepatitis. Nature 1968; 218: 1057–59.
Campbell S, Vogt VM. In vitro assembly of virus-like particles with Rous sarcoma virus gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles. J Virol 1997; 71: 4425-35.
Bragard C, Duncan GH, Wesley SV, Naidu RA, Mayo MA. Virus-like particles assemble in plants and bacteria expression the coat protein gene of Indian peanut clump virus. J Gen Virol 2000; 81: 267-72.
Overby AK, Popov V, Neve EPA, Pettersson RF. Generation and analysis of infectious virus-like particles of Uukuniemi virus (Bunyaviridae): a useful system for studying bunyaviral packing and budding. J Virol 2006; 80: 10428-35.
Gerber S, Lane C, Brown DM, et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 2001; 75: 4752-60.
Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 2001; 13: 633-41.
Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer’sdisease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine 2006; 24: 6321-31.
Millian AFS, Ortigosa SM, Hervas-Stubbs S, et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 2008; 6: 427-41.
Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, Caldeira JC, Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 2008; 380: 252-63.
Brandler S, Ruffie C, Combredet C, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013; 31: 3718-25.
Taylor TJ, Diaz F, Colgrove RC, et al. Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 2016; 496: 186-93.
Schoonen L, Maassen S, Nolte RJM, van Hest JCM. Stabilization of virus-like particle and its application as a nanoreactor at physiological conditions. Biomacromolecules 2017; 18: 3492-97.
Lou F, Huang P, Neetoo H, et al. High-pressure inactivation of Human norovirus virus-like particles provides evidence that the capsid of Human norovirus is highly pressure resistant. Appl Environ Microbiol 2012; 78: 5320-27.
Liew MWO, Rajendran A, Middelberg APJ. Microbial production of virus-like particle vaccine protein at gram-per-litre levels. J Biotechnol 2010; 150: 224–31.
Guo H, Zhu J, Tan Y, et al. Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits. Antiviral Res 2016; 131: 85-91.
Sinnuengnong R, Attasart P, Smith DR, Panyim S, Assavalapsakul W. Administration of co-expressed Penaeus stylirostris densovirus-like particles and dsRNA-YHV-Pro provide protection against yellow head virus in shrimp. J Biotechnol 2018; 267: 63-70.
Goh ZH, Tan SG, Bhassu S, Tan WS. Virus-like particles of Macrobrachium rosenbergii nodavirus produced in bacteria. J Virol Methods 2011; 175: 74-79.
Sinnuengnong R, Attasart P, Smith DR, Panyim S, Assavalapsakul W. In vitro assembly of Penaeus monodon densovirus (PmDNV)-like particles produced in a prokaryote expression system. Aquac Res 2017; 48: 4975-81.
Zhang C, Ku Z, Liu Q, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 2015; 33: 2335-41.
Wi GR, Hwang JY, Kwon MG, Kim HJ, Kang HA, Kim HJ. Protective immunity against nervous necrosis virus in convict grouper Epinephelus septemfasciatus following vaccination with virus-like particles produced in yeast Saccharomyces cerevisiae. Vet Microbiol 2015; 177: 214-18.
Zhou Y, Shen C, Zhang C, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res 2016; 132: 165-69.
Lee HJ, Kim JY, Kye SJ, Seul HJ, Jung SC, Choi KS. Efficient self-assembly and protective efficacy of infectious bursal disease virus-like particles by a recombinant baculovirus co-expressing precursor polyprotein and VP4. Virol J 2015; 12: 1-9.
Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1. Protein Expr Purif 2015; 116: 7-11.
Kueh CL, Yong CY, Dezfooli SM, Bhassu S, Tan SG, Tan WS. Virus-like particle of Macrobrachium rosenbergii Nodavirus produced in Spodoptera frugiperda (Sf9) cells is distinctive from that produced in Escherichia coli. Biotechnol Prog 2016; 33: 549-57.
Catrice EVB, Sainsbury F. Assembly and purification of polyomavirus-like particles from plants. Mol Biotechnol 2015; 57: 904-913.
Kessans SA, Linhart MD, Meador LR, et al. Immunological characterization of plant-based HIV-1 gag/dgp41 virus-like particles. Plos One 2016; 1-19.
Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front Microbiol 2022; 12: 1-20.
Dai S, Wang H, Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. J Immunol Sci 2018; 2: 36-41.
Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol 2021; 19: 1-27.
Grataitong K, Huault S, Chotwiwatthanakun C, et al. Chimeric virus-like particles (VLPs) designed from shrimp nodavirus (MrNV) capsid protein specifically target EGFR-positive human. Sci Rep 2021; 11: 1-11.
Yong CH, Yeap SK, Goh ZH, Ho KL, Omar AR, Tan WS. Induction of humoral and cell-mediated immune response by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus. Appl Environ Microbio 2015; 81: 882-89.
Donaldson B, Lateef Z, Walker GF, Young SL, Ward VK. Virus-like particle vaccines: immunology and formulation for clinical translation. Expert Rev Vaccines 2018; 17: 833-49.
Lin MC, Shen CH, Chang D, Wang M. Inhibition of human lung adenocarcinoma growth and metastasis by JC polyomavirus-like particles packaged with an SP-B promoter-driven CD59- specific shRNA. Clin Sci 2019; 133: 2159-69.
Thong QX, Biabanikhankahdani R, Ho KL, Alitheen NB, Tan WS. Thermally-responsive virus-like particle for targeted delivery of cancer drug. Sci Rep 2019; 9: 1-14.
Sakai C, Hosokawa K, Watanabe T, et al. Human hepatitis B virus-derived virus-like particles as a drug and DNA delivery carrier. Biochem Biophys Res Commun 2021; 581: 103-9.
Yan D, Teng Z, Sun S, et al. Foot-and-mouth disease virus-like particles as integrin-based drug delivery system achieve targeting anti-tumor efficacy. Nanomed: Nanotechnol Biol Med 2017; 13: 1061-70.
Sun X, Li W, Zhang X, et al. In vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of Simian virus 40. Nano Lett 2016; 16: 6164-71.
Sunkla S, Dickmeis C, Nagarajan AS, Fischer R, Commandeur U, Steinmetz NF. Molecular farming of fluorescent virus-based nanoparticles for optical imaging in plants, human cell and mouse models. Biomater Sci 2014; 2: 784-97.
Tagit O, de Ruiter MV, Brasch M, Ma Y, Cornelissen JJLM. Quantum dot encapsulation in virus-like particles with tuneable structure properties and low toxicity. RSC Adv 2017; 7: 38110-18.
Xiao Y, Zhang S, Yan H, et al. The high immunity induced by the virus-like particles of foot-and- mouth disease virus serotype O. Front Vet Sci 2021; 8: 1-10.
Park BR, Bommireddy R, Chung DH, et al. Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice. Immun Ageing 2023; 20: 1-14.
Hodgins B, Pillet S, Landry N, Ward BJ. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities. Plos One 2019; 14: 1-13.
Ward BJ, Gobeil P, Seguin A, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med 2021; 27: 1071-1078.
Park JE, Kim JH, Park JY, Jun SH, Shin HJ. A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge. Virol J 2022; 19: 1-10.
Ishii H, Nakamura-Hoshi M, Shu T, Matano T. Sendai virus particles carrying target virus glycoproteins for antibody induction. Vaccine 2022; 40: 2420-2431.
Huertas-Diaz MC, Phan S, Elson A, et al. Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens protect mice against RSV infection. Vaccine 2019; 37: 2925-2934.
Zhou Y, McNamara RP, Dittmer DP. Purification methods and the presence of RNA in virus particles and extracellular vesicles. Viruses 2020; 12: 1-15.
Downloads
เผยแพร่แล้ว
How to Cite
ฉบับ
บท
License
Copyright (c) 2023 วารสารเทคนิคการแพทย์
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
